Ignite Creation Date:
2024-07-17 @ 10:44 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06489717
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-28
Brief Title:
High Altitude Residents With High Altitude Pulmonary Hypertension HAPH SDB Assessed at HA 3200 m vs LA 760 m
Sponsor:
University of Zurich
Organization:
University of Zurich
Study Overview
Official Title:
Comparative Study of Sleep Disordered Breathing SDB in Patients With High Altitude Pulmonary Hypertension Permanently Residing Above 2500 Meters When Assessed Near Resident High Altitude HA at 3200 m vs at Low Altitude LA 760 m
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study the effect of relocation from 3200m Aksay to 760m Bishkek in highlanders with High Altitude Pulmonary Hypertension HAPH who permanently live 2500m on sleep disordered breathing
Detailed Description:
This research in highlanders with HAPH diagnosed by echocardiography and defined by a RVRA 30 mmHg who permanently live at HA 2500 m will have nocturnal respiratory sleep studies near their living altitude in Aksay at 3200 m and on night 1 and 6 at 760m after relocation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None